ArticleScientific reports2025
Association of ABCB1 G2677T polymorphism with atorvastatin lipid efficacy and extended prognosis in patients with cerebral ischemic stroke.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thrombophilia and Folate Cycle Gene Polymorphisms in the Development of Ischemic Stroke After COVID-19.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To investigate the association between ABCB1 (2677T > G) (rs2032582) polymorphism and lipid-lowering efficacy of atorvastatin with long-term prognosis in patients with cerebral ischemic stroke (CIS). A prospective cohort of 127 CIS patients admitted to Xuchang Central Hospital from January to December 2021 was consecutively enrolled. ABCB1 (2677T > G) genotypes were determined using digital fluorescence molecular hybridization technology, categorizing patients into GG (n = 48), GT (n = 49), and TT (n = 30) groups. All patients received oral atorvastatin 20 mg/day. Lipid profile changes (pre-treatment vs. 2-month post-treatment) were analyzed via analysis of covariance (ANCOVA). Treatment efficacy was defined as achieving serum LDL-C < 1.8 mmol/L, and binary logistic regression analysis was used to explore the impact of ABCB1(2677T > G) gene polymorphism on the lipid-lowering efficacy of atorvastatin. All patients were followed up for 36 months post-discharge to compare differences in long-term prognosis among the three groups. Genotype distribution followed Hardy-Weinberg equilibrium (χ
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.